Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor model

28 Dec 2023

Abstract excerpt

Background The GL261 and CT2A syngeneic tumor lines are frequently used as immunocompetent orthotopic mouse models of human glioblastoma (huGBM) but demonstrate distinct differences in their responses to immunotherapy. Methods To decipher the cell-intrinsic mechanisms that drive immunotherapy resistance in CT2A-luc and to define the aspects of human cancer biology that these lines can best model, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Glioma Diagnosis and Treatment
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38213329
DOI: 10.3389/fimmu.2023.1297932

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antigen presentation deficiency, mesenchymal differentiation, and resistance to immunotherapy in the murine syngeneic CT2A tumor modelPMID 38213329Read ↗

Functional profiling of murine glioma models highlights targetable immune evasion phenotypes.Semantic proximity Read ↗

Integrated spatial and single-cell transcriptomic analysis of aggressive glioblastoma growth dynamicsSemantic proximity Read ↗

Molecular and cellular phenotypic differences distinguish murine syngeneic models from human tumorsSemantic proximity Read ↗

Functional profiling of murine glioma models highlights targetable immune evasion phenotypesSemantic proximity Read ↗

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery.Semantic proximity Read ↗

Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumorsSemantic proximity Read ↗

The Original M2 And M6 Mouse Models Of Glioblastoma: Morphological And Molecular Characteristics Of Transplanted Tumor TissueSemantic proximity Read ↗

Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma.Semantic proximity Read ↗

A novel neural stem cell-derived immunocompetent mouse model of glioblastoma for preclinical studiesSemantic proximity Read ↗

Genetic driver mutations introduced in identical cell-of-origin in murine glioblastoma reveal distinct immune landscapes but similar response to checkpoint blockade.Semantic proximity Read ↗

Immune landscape of a genetically-engineered murine model of glioma relative to human glioma by single-cell sequencingSemantic proximity Read ↗

Advanced HCC precision modeling reveals divergent responses to combinatorial immunotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.